Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773847 | 0.80 | SMN1; SMN2 (0.41) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL3905827 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL2968730 | 0.78 | RAB9A (0.40) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL3905814 | 0.78 | NPC1 (0.30) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL16238698 | 0.74 | ALDH1A1 (0.35) | NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL3901618 | 0.73 | ALDH1A1 (0.30) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL3902141 | 0.72 | KMT2A (0.46) | NPC1CYP2C9CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL3901356 | 0.71 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3909352 | 0.68 | PARP1 (0.35) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3900149 | 0.67 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658072-A4 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | claimed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | claimed |
| EP-1658072-A4 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080249094-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-10-09 | — | — | US | disclosed |
| US-7408068-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, BACE1, PSEN1 | NPC1 125/4885CYP1A2 3823/4885CYP2C9 4639/4885 |
| US-20080249094-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, BACE1, PSEN1 | NPC1 125/4885CYP1A2 3823/4885CYP2C9 4639/4885 |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | APP, BACE1, PSEN1 | NPC1 125/4885CYP1A2 3823/4885CYP2C9 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.